Bispecific Antibodies Market (By Indication: Cancer, Inflammatory & Autoimmune disorders) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global bispecific antibodies market was valued at USD 5.77 billion in 2022 and it is predicted to surpass around USD 221.67 billion by 2032 with a CAGR of 44.03% from 2023 to 2032. The bispecific antibodies market in the United States was accounted for USD 4.8 billion in 2022.

Key Pointers

• North America accounted for the largest market share of 90% in 2022. 
• Europe is estimated to grow at the fastest CAGR of 52.44% from 2023 to 2032.
• Cancer segment dominated the market in 2022 with a market share of 71%. 
• The inflammatory and autoimmune disorders segment is expected to grow at a significant CAGR of 35.75% during 2023-2032.

Report Scope of the Bispecific Antibodies Market

Rising incidences of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, rising demand for targeted therapies as well as advancements in antibody engineering technologies are some major driving factors that propel the market growth. According to a report published in 2022 by the National Association of Chronic Disease Directors, over 60% of adult Americans have at least one chronic disease.

Furthermore, according to the Centers for Disease Control and Prevention, people with chronic diseases and mental health disorders account for 90% of the nation's $3.8 trillion in annual healthcare expenditure. To deal with such conditions, bispecific antibodies provide a promising avenue for personalized medicine and targeted interventions in these disease areas. Moreover, rising approval for several bispecific antibodies by regulatory bodies has surged the interest and confidence of companies to invest in research and development.

For instance, in October 2022, the FDA approved Teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen for adult patients with relapsed or refractory multiple myeloma. Additionally, companies are actively engaging in collaborations and partnerships to leverage complementary expertise and technologies to develop bispecific antibodies. These collaborations lead to accelerated research and development activities, further boosting the overall market growth.

The COVID-19 pandemic had a neutral effect on the market. The increased emphasis on biologic therapies and their potential for COVID-19 treatment positively influenced the market. However, disruptions in clinical trials, supply chain challenges, diverted resources, and strained healthcare systems posed obstacles.

Indication Insights

Cancer segment dominated the market in 2022 with a market share of 71%. Cancer is a leading cause of mortality globally, with a high prevalence in various populations. As per the World Health Organization (WHO) report, cancer accounted for nearly 609,360 deaths in 2022 in the U.S. The significant burden of cancer drives the demand for innovative therapies, including bispecific antibodies, which can target multiple tumor-associated antigens simultaneously, enhancing therapeutic efficacy.

Currently, several treatment options are available to treat cancer-related diseases; however, despite several treatment choices, certain types of cancer still have limited treatment options. Bispecific antibodies offer a promising approach for addressing this challenge by targeting multiple pathways or antigens involved in cancer progression, potentially leading to improved patient outcomes. Bispecific antibodies specifically target cancer cells or tumor-associated antigens while sparing healthy cells. This high target specificity minimizes off-target effects and reduces toxicity compared to traditional therapies, making bispecific antibodies an attractive option for cancer treatment.

The inflammatory and autoimmune disorders segment is expected to grow at a significant CAGR of 35.75% during 2023-2032. Inflammatory and autoimmune disorders encompass various conditions, such as rheumatoid arthritis, psoriasis, Crohn's disease, and multiple sclerosis. These disorders often have a significant impact on a patient's quality of life and can lead to chronic inflammation, tissue damage, and organ dysfunction. Many patients with these conditions experience inadequate response or intolerance to existing therapies, creating significant unmet medical needs.

For instance, per the National Center for Biotechnology Information report published in 2022, rheumatoid arthritis is one of the most popular chronic diseases, with a prevalence of 460 per 10,000 people.  Inflammatory and autoimmune disorders have complex and multifaceted mechanisms, including dysregulated immune responses, cytokine imbalances, and abnormal cell signaling pathways. Traditional therapies often target a single molecular target or pathway, limiting their efficacy. Bispecific antibodies, such as tibulizumab, Ozoralizumab, and others can engage multiple targets. These provide a more comprehensive approach to modulating these complex disease mechanisms, potentially leading to better outcomes. Bispecific antibodies are designed to simultaneously target two relevant molecules involved in the disease process, allowing for greater flexibility and specificity in addressing the diverse range of targets necessitated by the disorder.

Regional Insights

North America accounted for the largest market share of 90% in 2022. The presence of several market players and various developments done by them are some key factors driving the region’s growth. Moreover, technological advancements, high investment in R&D, and rising demand for bispecific antibodies are other factors supporting the regional market.

Furthermore, rising approval for several bispecific antibodies by regulatory bodies has surged the interest and confidence of companies to invest in research and development. For instance, in October 2022, the FDA approved teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen. Additionally, companies are actively engaging in collaborations and partnerships to leverage complementary expertise and technologies to develop bispecific antibodies. These collaborations have led to accelerated research and development activities, further boosting the overall market growth.

Europe is estimated to grow at the fastest CAGR of 52.44% from 2023 to 2032. The region benefits from a favorable regulatory environment and a focus on precision medicine, which aligns with the unique capabilities of bispecific antibodies. Collaborations and partnerships between local and international stakeholders further contribute to the region's growth. These factors collectively position the region as a promising market with significant growth potential for bispecific antibodies.

Bispecific Antibodies Market Segmentations:

By Indication 

• Cancer
• Inflammatory & Autoimmune Disorder
• Others

By Regional 

• North America
  • The U.S.
  • Canada
• Europe
  • U.K.
  • Germany
• Asia Pacific
  • Japan
  • China
• Rest of the World